Impression Healthcare (ASX: IHL) has confirmed in it quarterly report that it has sourced all permits and products required for the start of animal pre-clinical testing of cannabinoid drug IHL-675A developed to treat sepsis-related adult respiratory distress syndrome (ARDS), which is considered the leading cause of death from COVID-19.
